BTNL10 Activators
BTNL10, a member of the butyrophilin-like protein family, is predicted to enable signaling receptor binding activity. Its precise functions include involvement in immune response and cellular activities. To explore potential activators, we considered various chemicals that impact related pathways. The activation of BTNL10 is influenced by various chemicals indirectly targeting key signaling pathways. LY294002 indirectly activates BTNL10 by inhibiting PI3K, modulating PI3K-dependent pathways related to immune response and cellular functions. SB202190, a p38 MAPK inhibitor, influences BTNL10 indirectly by altering p38 MAPK-dependent pathways associated with signaling receptor binding and cellular activation. Wortmannin, another PI3K inhibitor, indirectly impacts BTNL10 through similar mechanisms as LY294002.
SP600125, a JNK inhibitor, affects BTNL10 indirectly by modulating JNK-dependent pathways related to signaling receptor binding and cellular activation. Rapamycin, an mTOR inhibitor, indirectly activates BTNL10 by impacting mTOR-dependent pathways associated with immune response and cellular functions. PD 169316, another p38 MAPK inhibitor, indirectly affects BTNL10 through mechanisms similar to SB202190. BAY 11-7082, an NF-κB inhibitor, impacts BTNL10 indirectly by modulating NF-κB-dependent pathways associated with immune response and cellular functions. AZD8055, an mTOR inhibitor, influences BTNL10 indirectly by modulating mTOR-dependent pathways associated with immune response and cellular functions. In summary, the activation of BTNL10 is intricately linked to various signaling pathways modulated by these chemicals, influencing processes related to immune response and cellular functions. The nuanced interplay between these activators and BTNL10 highlights the complexity of the molecular mechanisms involved in the regulation of immune responses and cellular activities mediated by butyrophilin-like proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor influencing BTNL10 indirectly. By inhibiting p38 MAPK, it modulates downstream signaling. BTNL10, predicted to enable signaling receptor binding activity, may be indirectly activated through altered p38 MAPK-dependent pathways, influencing processes related to signaling receptor binding and cellular activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor impacting BTNL10 indirectly. By inhibiting mTOR, it modulates downstream signaling. BTNL10, a butyrophilin-like protein, may be indirectly activated through altered mTOR-dependent pathways, influencing processes related to immune response and cellular functions. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
p38 MAPK inhibitor influencing BTNL10 indirectly. By inhibiting p38 MAPK, it modulates downstream signaling. BTNL10, predicted to enable signaling receptor binding activity, may be indirectly activated through altered p38 MAPK-dependent pathways, influencing processes related to signaling receptor binding and cellular activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor affecting BTNL10 indirectly. By inhibiting NF-κB, it modulates downstream signaling. BTNL10, a butyrophilin-like protein, may be indirectly activated through altered NF-κB-dependent pathways, influencing processes related to immune response and cellular functions. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
PI3K inhibitor indirectly impacting BTNL10. By inhibiting PI3K, it modulates downstream signaling. BTNL10, predicted to enable signaling receptor binding activity, may be indirectly activated through altered PI3K-dependent pathways, influencing processes related to signaling receptor binding and cellular activation. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
mTOR inhibitor impacting BTNL10 indirectly. By inhibiting mTOR, it modulates downstream signaling. BTNL10, a butyrophilin-like protein, may be indirectly activated through altered mTOR-dependent pathways, influencing processes related to immune response and cellular functions. | ||||||
Ampeloptin | 27200-12-0 | sc-480419 | 10 mg | $300.00 | ||
JNK inhibitor affecting BTNL10 indirectly. By inhibiting JNK, it modulates downstream signaling. BTNL10, predicted to enable signaling receptor binding activity, may be indirectly activated through altered JNK-dependent pathways, influencing processes related to signaling receptor binding and cellular activation. | ||||||